Strong growth & margin expansion via specialty shift; new capacity unlocking next phase

Delivered ₹534.3 Cr revenue, ₹84.8 Cr PAT, 24.2% OPM — exact match

Call states 67.7% despite higher input/freight costs. Driven by exiting lower-margin business.

Q1 USD revenue $55M up 32% YoY but down sequentially due to tactical measures. Q2 explicitly flagged as 'tracking strong.' Claim is forward-looking; cannot verify.

Prior guidance 22-23%. Call states 'slightly up guiding' to 'around 23%' — slight, measured upgrade within range.

Stated as achieved this quarter; validates strong core unit economics.

Prior 22-23%, now 'comfortable to revise upwards to ~23%' — management signaling confidence in hitting upper end despite ESOP, Arinna, pre-revenue facility costs.

Now 36% of gross profit (vs baseline context earlier quarters). Specialty revenue up YoY despite USD revenue tactical dip; mix improving.

New Jersey acquisition (USD 2.9M, FDA-compliant) adds onshore US capacity & government business enablement. Strategic, not financial, rationale but medium-term revenue/margin upside.

Nitin (CFO) → Chief Commercial Officer; Rohit designate CFO. Signaling succession planning & scaling commercial function. No red flag; well-sequenced.

Broad-based growth across all products, even 8-10 year old launches. Portfolio concentration trending down over time. Conservative on product pipeline disclosure due to competitive sensitivity.

Actively adopting technology (automation, AI, others) for efficiency & compliance. Regulatory scrutiny is key constraint; all tools must demonstrate robust, repeatable results to FDA. No specific AI comment given evolving landscape.

Approvals per plan; company conservative on revenue forecasting from new approvals. Portfolio approach unchanged; no pivot to fewer, bigger bets.

Strategic move, not margin-dilutive. Margin-accretive overall. Focus on value-added products + supply-chain diversification + government sales. No margin impact baked into forecasts.

Competitive sensitivity; company discloses specialty share of gross profit (~36% this quarter) and product count once per year. Will not expand specialty-specific disclosures.

Pithampur ~30 acres; using 5-6 acres. Space available = greater than footprint of all other sites combined. CSN facility modularly ready for niche dosage forms. Significant expansion headroom short & long-term.

Mix of own manufacturing, outsourced, traded goods, and sales productivity. Gross margin focused on; transfer pricing fully compliant & no sharp movements. Offered offline clarification on detailed math.

Management acknowledged risk, did not provide specific mitigation strategy beyond new US manufacturing footprint (long-term hedge). No short-term hedging detailed.

Phased approach: Phase 1 (now) identify & fix growth levers. Phase 2 beat IPM growth. Phase 3 profitability. EBITDA guidance at consolidated level, already accounts for Arinna growth investment.

Court-supervised bankruptcy process. Long deal process (>1.5 yrs). Patient capital approach focused on long-term value. Adjacent to existing distribution hub (AIMRX 3PL). Ability to build revenue/profit multipliers on acquired assets (track record: Satara, Impopharma).

Portfolio approach. Risk, probability, execution ease, org maturity considered. Long-term high-innovation + shorter-cycle competitive-advantage products. No concentration on few big bets.

Portfolio-driven, not cost-driven. Ambernath (oral/nasal), Satara (liquids + nasal backup), Indore (steroids, hormones, high-potency), Pithampur (large scale), CSN (niche dosage). Risk diversification & business continuity for customers. Capex lags sales; outsourcing bridge during ramp-up.

Yes. Specialty share in GP increased. Walked away from lower-margin business only if securing higher-margin replacement. Strategic choice to improve mix.

Q1 CY2027 commercialization targeted. Enough capacity for short-term ramp. 9-12M gradual scale-up. Long-term: massive headroom on 30-acre site (using 5-6). Expansion quick given land available.

Disclosed once per year (last quarter). Will share updated number annually, not quarterly.

No numeric revenue CAGR given. USD Q2 flagged as 'tracking strong sequential growth' post-tactical Q1 dip. YoY growth momentum (51% YoY in Q1) expected to continue.

Despite ESOP costs, Arinna growth invest, pre-revenue facility costs, mgmt confident in upper-end delivery. Operating EBITDA at 24.2% in Q1, within guidance.

On track: ₹251 Cr spent in 5 qtrs. Q1 FY27 R&D 10.9% of revenue; expected to remain 10-11% industry-leading level.

Both on regulatory timelines; capacity headroom substantial (Pithampur 30 acres, using 5-6).

Outsourced manufacturing peaked in last 3-4 quarters due to manufacturing constraints. Tactical exit from lower-margin business improved mix but is finite. Own manufacturing ramp critical.

97% revenue exposure to US exports. Tariff imposition would directly impact realized pricing & competitiveness. New Jersey facility being positioned for onshore exemptions, but ramp timeline (CY2027) may lag potential tariff implementation.

Arinna acquired April 2026; Q1 contribution ₹12 Cr revenue, zero material EBITDA. Phased approach (Phase 1: identify growth levers; Phase 2: IPM growth; Phase 3: profitability) extends profit realization to FY28+. Integration execution risk; market conditions may shift during build-out.

Pithampur (₹1,500M capex, pre-revenue) targeting Q1 CY2027 ramp-up; New Jersey facility (USD 2.9M acquisition) targeting CY2027 ops. Parallel ramp-ups carry execution risk. Revenue visibility stated but quantified guidance lacking. CSN modular facility timing unknown.

Nitin Jajodia (CFO, 5 years) transitioning to Chief Commercial Officer role; Rohit (CFO designate) joining as replacement. During facility ramps, capital deployment & working capital management critical. Transition well-communicated but execution risk on handoff.